Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences, Inc. : Gilead Sciences to Present at the NASDAQ OMX 29th Investor Program

12/03/2012 | 04:35pm EDT

- Webcast Available Through Gilead Corporate Website -

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company will be webcasting its corporate presentation at the NASDAQ OMX 29th Investor Program in London.

Kevin Young CBE, Gilead's Executive Vice President of Commercial Operations, will provide an overview of the company on Tuesday, December 4 at 8:30 a.m. Greenwich Mean Time (3:30 a.m. Eastern Time).

To access the live webcast or a replay via the Internet, log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary to listen to the webcast. The replay will be available for 14 days following the presentation.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

Gilead Sciences, Inc.
Patrick O?Brien
Investor Relations
650-522-1936


© Business Wire 2012
All news about GILEAD SCIENCES, INC.
05/05EVEREST MEDICINES'  : Breast Cancer Therapy Wins Orphan Drug Designation in Sout..
MT
05/04GILEAD SCIENCES  : Eli Lilly to supply 400,000 tablets of its COVID-19 treatment..
RE
05/04Eli Lilly Accelerates Baricitinib Availability in India Amid Covid-19 Surge
DJ
04/30Vaccitech, startup behind Oxford COVID-19 vaccine tech, falls 20% in Nasdaq d..
RE
04/30Vaccitech, startup behind Oxford COVID-19 vaccine tech, falls 20% in Nasdaq d..
RE
04/30GILEAD SCIENCES  : Morgan Stanley Adjusts Price Target on Gilead Sciences to $83..
MT
04/30GLOBAL MARKETS LIVE : Nestlé, Schindler, Credit Suisse
04/30Today on Wall Street: A quiet end to April
04/30NEWS HIGHLIGHTS  : Top Company News of the Day
DJ
04/29S&P 500 near record high on Facebook boost, Nasdaq eases
RE
More news
Financials (USD)
Sales 2021 24 706 M - -
Net income 2021 6 975 M - -
Net Debt 2021 21 984 M - -
P/E ratio 2021 12,5x
Yield 2021 4,23%
Capitalization 83 740 M 83 740 M -
EV / Sales 2021 4,28x
EV / Sales 2022 4,18x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 75,08 $
Last Close Price 66,51 $
Spread / Highest target 50,4%
Spread / Average Target 12,9%
Spread / Lowest Target -9,79%
EPS Revisions
Managers and Directors
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Richard J. Whitley Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.12.67%83 740
WUXI APPTEC CO., LTD.17.84%59 429
VERTEX PHARMACEUTICALS-9.51%55 364
REGENERON PHARMACEUTICALS0.43%49 948
BIONTECH SE109.48%41 245
BEIGENE, LTD.18.19%28 155